Skip to main content
. 2021 Apr;10(4):1418–1430. doi: 10.21037/gs-21-84

Figure 3.

Figure 3

DNA hypomethylation promotes the upregulation of LINC00511 in breast cancer. (A) DNA methylation of the LINC00511 promoter region was decreased in 14 cancer types. (B) LINC00511 was negatively correlated with DNA methylation in BRCA. (C) DNA methylation of the LINC00511 promoter region in pan-cancer tissues was lower compared to normal tissues (T=8,989) in TCGA (https://tcga-data.nci.nih.gov/). (D) LINC00511 was negatively correlated with DNA methylation in pan-cancer (N=8,451). ****, P<0.0001. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangio carcinoma; COAD, colon adenocarcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; TCGA, The cancer genome atlas.